ReviewEndocrine connections2026
Perioperative management of patients with primary aldosteronism: a practical approach for the endocrinologist.
Review in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is the most common endocrine cause of secondary hypertension yet remains significantly underdiagnosed. Early recognition is essential, as excess aldosterone leads to substantial cardiovascular and renal morbidity. Approximately one-third of patients have unilateral disease, in whom adrenalectomy is associated with superior long-term clinical outcomes compared with medical therapy. Although current guidelines offer detailed recommendations for diagnosis and subtype classification, guidance on perioperative management remains limited. Preoperative goals should include optimizing blood pressure to <140/90 mmHg and correcting potassium levels, which can be achieved by initiating mineralocorticoid receptor antagonists (MRAs) in all patients. MRA titration ensures effective receptor blockade and supports recovery of contralateral adrenal function. A dedicated preoperative endocrinology consultation is essential to review expected surgical outcomes, address the anticipated postoperative decline in renal function, evaluate cortisol co-secretion, and assess the risk of postoperative adrenal insufficiency. Postoperatively, the primary concern is hyporeninemic hypoaldosteronism. Antihypertensive medications should be down-titrated, MRAs withheld, and a high-sodium diet encouraged. Early biochemical assessment does not establish cure but may still provide clinically relevant information. Follow-up includes weekly assessments during the first month and structured evaluation of clinical and biochemical outcomes at 6-12 months using the PASO criteria. Histological findings help predict recurrence risk and decide long-term follow-up. Patients achieving complete biochemical success, along with a complete or partial clinical response and having classic histopathological features, may transition to long-term follow-up in a primary care setting. This manuscript proposes a structured perioperative management approach for patients with PA undergoing adrenalectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.